A total of @ patients with refractory or sensitive SCLC were randomly assigned at a ratio of @:@ to @-day cycles of amrubicin @ mg/m ( @ ) intravenously ( IV ) on days @ to @ or topotecan @ mg/m ( @ ) IV on days @ to @ .